BAFF levels were significantly higher in patients receiving IFN-β treatment compared to untreated MS patients (Tukey HSD test, P = 0.00085) and patients treated with GA (Tukey HSD test, P = 0.0042). The gene discussed is TNFSF13B; the disease is myeloid sarcoma.